This policy differentiates germline risk‑assessment panels from therapeutic somatic tumor testing. Germline multigene panels are intended to assess inherited cancer risk in asymptomatic or at‑risk individuals based on personal and/or family history, whereas somatic tumor testing is performed on tumor tissue to identify somatic variants that may direct targeted therapy. Coverage guidance in this policy applies to germline testing for hereditary cancer susceptibility and does not apply to somatic tumor profiling done for therapeutic decision‑making.

No explicit coverage exclusions are listed in the excerpted gene summaries. The policy notes that state and federal mandates and member contract provisions take precedence and should be verified prior to ordering, but does not specify additional categorical exclusions in this portion of the document.

Multigene panel uses that do not meet the medical necessity criteria (policy A.1–A.3) are classified as experimental/investigational and are not supported under this policy. The policy specifies that coverage for panels is contingent on meeting one of the listed coverage criteria (eg, meeting related policy criteria, prior limited testing with persistent suspicion, or family pathogenic variant not fully explanatory).

The policy highlights that large, comprehensive panels are associated with higher rates of variants of uncertain significance (VUS) and more incidental or unexpected findings not directly related to the presenting cancer. Reported VUS rates rise with panel size and have been observed to approach ~50% for large gene panels, which increases the likelihood of results that may not change clinical management.

Expanded panels that include genes with unknown or variable cancer risk have uncertain clinical validity. Because management recommendations for low‑to‑moderate penetrance genes are not standardized, the clinical utility for many genes on expanded panels is uncertain and may lead to potential harm or unclear management pathways.

The policy states that all other uses of multigene panels for genetic cancer susceptibility testing that do not meet specified criteria are considered experimental/investigational. Expanded or unfocused panels beyond the recommended, indication‑specific gene sets fall into this category.

Within the excerpted portions of the document there are no additional explicit exclusions listed beyond those described under the policy’s experimental/investigational statements and the guidance to verify member contract provisions and state/federal mandates.

The gene‑specific summaries included in this excerpt do not contain statements declaring particular genes or tests as not medically necessary. Instead, the policy uses group‑level criteria to determine whether panel testing is supported.

Panels that do not meet the policy’s stated criteria (for example, those ordered without a qualifying personal/family history or not meeting related policy criteria) are not supported by this policy and are considered experimental/investigational.

For many genes included on expanded panels, the chain of evidence linking analytic validity to clinical validity and then to clinical utility is incomplete. When clinical validity for specific genes is not established, the downstream evidence for clinical utility is lacking, limiting the ability to justify their inclusion for routine clinical decision‑making.

The policy reiterates that general genetic cancer susceptibility panel testing is considered experimental/investigational except in circumstances covered by the policy criteria or when coverage is governed by other, syndrome‑specific policies. Limited, indication‑focused panels that meet coverage criteria may be considered medically necessary.

The policy discourages ordering sequencing in unaffected relatives before testing an affected family member when available. It recommends that, when possible, initial testing be performed in an affected family member so unaffected relatives can undergo targeted variant testing for a known familial pathogenic variant, reducing uninformative negative results.

ELIGIBILITY REQUIREMENTS: The excerpt contains no top‑level eligibility nodes. Coverage is tied to the general statement that testing applies to individuals with a documented personal and/or family history suggestive of an inherited cancer syndrome; specific numeric or categorical eligibility thresholds are not provided in this section.

ELIGIBILITY REQUIREMENTS: No discrete top‑level eligibility nodes are present in this excerpt. The policy’s applicability rests on documented personal and family history consistent with inherited cancer risk rather than prespecified checklist items in the provided text.

ELIGIBILITY REQUIREMENTS: The relevant population for germline testing comprises individuals with a documented personal and/or family history suggestive of an inherited cancer syndrome (eg, early‑onset cancer, multiple primaries, or a family pattern consistent with known syndromes). Testing consideration is driven by whether results would provide predictive information that could change management or surveillance.

ELIGIBILITY REQUIREMENTS: The policy refers to established guideline criteria (eg, NCCN) for genetic risk evaluation; documented family history including first‑ and second‑degree relatives and ethnicity should be recorded to guide panel selection. Individuals meeting those guideline criteria are the intended population for testing.

ELIGIBILITY REQUIREMENTS: The policy emphasizes that testing is intended for people whose personal and/or family histories suggest inherited susceptibility. The excerpt does not enumerate numeric cutoffs but indicates that eligibility hinges on whether testing would inform management.

ELIGIBILITY REQUIREMENTS: Individuals with early‑onset cancers, multiple primary tumors, or first‑degree relatives with relevant cancers are examples of the populations for whom germline multigene testing may be appropriate when findings would alter clinical care.

ELIGIBILITY REQUIREMENTS: No additional top‑level nodes are provided in this excerpt; the policy’s eligibility framework is based on documented clinical and family history suggestive of an inherited cancer syndrome.

ELIGIBILITY REQUIREMENTS: No discrete eligibility nodes are specified here; determination of appropriateness should be grounded in the documented history and guideline concordant risk assessment.

ELIGIBILITY REQUIREMENTS: This excerpt contains no additional structured eligibility criteria beyond the general requirement for a personal and/or family history suggestive of an inherited cancer syndrome.

ELIGIBILITY REQUIREMENTS: The document does not list further top‑level eligibility nodes in the provided text; clinical judgment aligned with guideline criteria is implied for determining eligibility.

ELIGIBILITY REQUIREMENTS: The evidence base and analyses referenced in the policy often compare patients with and without prior syndrome‑based or BRCA1/BRCA2 testing; prior targeted testing history may influence subsequent panel selection and coverage determinations in specific cases.

ELIGIBILITY REQUIREMENTS: Several studies and programmatic analyses referenced in the policy separate cohorts based on prior targeted testing (eg, prior BRCA testing), indicating that prior testing history is a relevant consideration when assessing the need for expanded panel testing.

ELIGIBILITY REQUIREMENTS: No additional top‑level eligibility nodes are present in this excerpt; eligibility decisions should be supported by documented personal/family history and applicable guideline criteria.

ELIGIBILITY REQUIREMENTS: The excerpted text does not provide further enumerated eligibility criteria beyond those already described; clinicians should reference the full policy and related syndrome‑specific policies for detailed thresholds.

BACKGROUND: Next‑generation sequencing (NGS) enables simultaneous evaluation of multiple genes and is commonly used for hereditary cancer risk assessment. While NGS increases testing efficiency and gene coverage, it also yields a higher number of variants of uncertain significance compared with direct sequencing and may identify findings that do not change management.

NOT COVERED: The policy cautions that broad or expanded panels can produce high rates of VUS and incidental findings that may not alter clinical management. When panels include genes without established clinical validity, results may not be actionable and therefore are not supported by the policy unless coverage criteria are met.

NOT COVERED: There are no specific named tests or indications listed as definitively not covered in the excerpted material. Coverage determinations depend on whether the ordered testing meets the policy criteria and member contract provisions.

NOT COVERED: The policy does not support expanded panels that are not justified by the individual’s personal and/or family history or that extend beyond the Table 1 recommended genes for the indicated cancer type without a clear potential benefit. Providers should document rationale when ordering broader panels.

NOT COVERED: Genes included on expanded panels that have unknown or variable cancer risk and for which clinical validity and utility have not been established are considered not covered in routine practice because they lack demonstrated clinical utility and may generate ambiguous results.

NOT COVERED: The policy considers expanded multigene panels and other uses of multigene panel testing that do not meet the policy’s specific criteria to be experimental/investigational and therefore not covered.

NOT COVERED: Within the provided excerpt there are no additional explicit test types or specific clinical indications declared as not covered; determinations are driven by the policy criteria and member contract language.